- You are viewing a Navigating Care library resource.
- Back to Library
Treatment of Monoclonal Gammopathy of Undetermined Significance
For information about the treatments listed below, see the Treatment Option Overview section.
Treatment of monoclonal gammopathy of undetermined significance (MGUS) is usually watchful waiting. Regular blood tests to check the level of M protein in the blood and physical exams to check for signs or symptoms of cancer will be done.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
November 1, 2024.
Learn more:
- General Information About Plasma Cell Neoplasms
- Stages of Plasma Cell Neoplasms
- Treatment Option Overview
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment of Isolated Plasmacytoma of Bone
- Treatment of Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Treatment of Relapsed or Refractory Multiple Myeloma
- To Learn More About Plasma Cell Neoplasms
Related Articles
- General Information About Plasma Cell Neoplasms
- Stages of Plasma Cell Neoplasms
- Treatment Option Overview
- Treatment of Monoclonal Gammopathy of Undetermined Significance
- Treatment of Isolated Plasmacytoma of Bone
- Treatment of Extramedullary Plasmacytoma
- Treatment of Multiple Myeloma
- Treatment of Relapsed or Refractory Multiple Myeloma
- To Learn More About Plasma Cell Neoplasms
More Resources
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
